Research programme: Molecular glues based therapeutics - BioTheryX
Latest Information Update: 04 Oct 2023
At a glance
- Originator BioTheryX
- Class
- Mechanism of Action CRBN protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase Unknown Unspecified
Most Recent Events
- 26 Sep 2023 Research programme: Molecular glues - BioTheryX is available for licensing as of 26 Sep 2023.
- 26 Sep 2023 Investigation in Unspecified in USA (unspecified route)